share_log

翰森製藥：根據債券持有人行使認沽期權贖回可換股債券

HANSOH PHARMA: REDEMPTION OF CONVERTIBLE BONDS PURSUANT TO EXERCISE OF PUT OPTION BY BONDHOLDERS

香港交易所 ·  Jan 22 07:03
Summary by Moomoo AI
翰森製藥集團有限公司（「翰森製藥」）於2024年1月22日公告，根據債券持有人的選擇，將贖回總額約5.91億美元的零息可換股債券，佔當日未贖回可換股債券本金總額的約99.10%。該操作將於2024年1月22日完成，並將由公司自有資金支付。公司表示，此次贖回不會對公司財務造成重大影響。贖回及註銷後，尚餘約538萬美元的可換股債券未被贖回，該部分債券可轉換為最多702,765股新股份，佔已發行股份約0.012%。公司董事會確認，持有未贖回可換股債券的人士及其最終實益擁有人均非公司的關連人士。
翰森製藥集團有限公司（「翰森製藥」）於2024年1月22日公告，根據債券持有人的選擇，將贖回總額約5.91億美元的零息可換股債券，佔當日未贖回可換股債券本金總額的約99.10%。該操作將於2024年1月22日完成，並將由公司自有資金支付。公司表示，此次贖回不會對公司財務造成重大影響。贖回及註銷後，尚餘約538萬美元的可換股債券未被贖回，該部分債券可轉換為最多702,765股新股份，佔已發行股份約0.012%。公司董事會確認，持有未贖回可換股債券的人士及其最終實益擁有人均非公司的關連人士。
Johnson Pharmaceuticals Group Limited (“Johnson Pharmaceuticals”) announced on January 22, 2024 that, at the option of the bondholders, it will redeem approximately US$5.91 million of zero-dividend convertible notes, representing approximately 99.10% of the outstanding convertible bond principal amount on the date. The operation will be completed on January 22, 2024 and will be paid for by the company's own funds. The Company stated that the redemption will not have a material impact on the Company's finances. Upon redemption and write-off, approximately $538 million of convertible notes outstanding have not been redeemed, which can be converted into up to 702,765 new shares representing approximately 0.012% of the issued shares. The Board of Directors of the Company confirms that the holders of the unredeemed convertible debentures and their ultimate beneficial owners are not affiliated persons of the Company.
Johnson Pharmaceuticals Group Limited (“Johnson Pharmaceuticals”) announced on January 22, 2024 that, at the option of the bondholders, it will redeem approximately US$5.91 million of zero-dividend convertible notes, representing approximately 99.10% of the outstanding convertible bond principal amount on the date. The operation will be completed on January 22, 2024 and will be paid for by the company's own funds. The Company stated that the redemption will not have a material impact on the Company's finances. Upon redemption and write-off, approximately $538 million of convertible notes outstanding have not been redeemed, which can be converted into up to 702,765 new shares representing approximately 0.012% of the issued shares. The Board of Directors of the Company confirms that the holders of the unredeemed convertible debentures and their ultimate beneficial owners are not affiliated persons of the Company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more